Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CSL Limited
The first close of a series C financing should enable InRhythm to enter Phase III as an inhalable anti-arrhythmic for paroxysmal atrial fibrillation in a medically supervised setting.
With the US filing of its non-sedative sleeping pill now imminent, the Swiss biotech is also adding to its war chest to advance Phase III drugs aprocitentan, clazosentan and lucerastat.
Keeping Track: Disappointment For Mesoblast And Aquestive; Opdivo/Yervoy Add Mesothelioma Claim; Pediatric Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Agency directs Sprout to disseminate corrective messages about the risks associated with the female sexual dysfunction pill. Sprout previously challenged FDA’s alcohol labeling requirements.
- Diagnostic Equipment & Supplies
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Other Names / Subsidiaries
- CSL Behring
- CSL Behring Mexico
- CSL Biotherapies
- CSL Bioplasma
- Wuhan Zhong Yuan Rui De Biological Products
- Calimmune, Inc.
- Vitaeris Inc.
- Zenyth Therapeutics Ltd.
- CSL, Ltd.